Peter Attia· MD
But even just take trastuzumab, the naked antibody, its ability to help a metastatic breast cancer patient live longer for a period of time, well cataloged, but measured in months, several months, let's say
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
But even just take trastuzumab, the naked antibody, its ability to help a metastatic breast cancer patient live longer for a period of time, well cataloged, but measured in months, several months, let's say
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
just an antibbody like welcome to modern oncology it was it could not have been more clear
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.